IVIG for autoimmune gut nerve disease that did not respond to other treatments
Records how people with autoimmune gut nerve problems respond to IVIG.
Key facts
- Who runs it
- University of Louisville
- Where
- Louisville, United StatesSee the site
- Trial code
- Registry title
- IVIG for Drug and Device Refractory Gastrointestinal Auto-Immune Neuropathy
- Status
- Recruiting
- People taking part
- 400 people, planned
- Started
- 2 Jan 2020
- Expected to end
- 2 Jan 2028
- Type of study
- Observational
- Record updated
- 1 August 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with gut movement problems, such as a slow-emptying stomach (gastroparesis), whose symptoms have not improved with other treatments. It follows how they respond to IVIG (immunoglobulin given into a vein).
- Age
- 12 Years to 90 Years
- Sex
- All
- Disease stage
- Symptoms of a gastrointestinal (GI) motor disorder that have not improved with other treatment.
- Earlier treatment
- Symptoms must have not improved with other treatments.
Main reasons for not taking part
- People who cannot receive intravenous immunoglobulin (IVIG) cannot join.
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- -
Who cannot take part
- -
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 12 and 90 years old?
Where in United States
- University of LouisvilleLouisville, United StatesContact: Thomas L AbellTaking people
About the trial
What the trial wants to find out
Patients with the symptoms of generalized GI dysmotility, including gastroparesis, are sometimes refractory to available medications, devices and other interventions/ Some of these patients have serologic and/or endo organ abnormalities and findings consistent with autoimmune neuropathies, primarily involving the GI tract. These disorders have been known as autoimmune gastrointestinal neuropathies (GAIN) or also as autoimmune gastrointestinal dysmotility (AGID), among other terms. Some patients respond to intravenous immunoglobulin (IVIG) and this study, which is an observational clinical series, documents the patients, their findings and standardized responses to therapy with IVIG.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- IVIG for Drug and Device Refractory Gastrointestinal Auto-Immune Neuropathy
- Plain-language title
- IVIG for autoimmune gut nerve disease that did not respond to other treatmentsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT04208828, who can take part
- Record updated
- 1 August 2025